2025
Novel Hemodynamic Markers and Kidney Function in Patients with Acute Decompensated Heart Failure
Tuttle M, Banlengchit R, Tighiouart H, Testani J, Moises A, Oka T, Ferguson K, Sarnak H, Harding C, Kiernan M, Sarnak M, McCallum W. Novel Hemodynamic Markers and Kidney Function in Patients with Acute Decompensated Heart Failure. Kidney360 2025, 6: 728-738. PMID: 40440457, PMCID: PMC12136642, DOI: 10.34067/kid.0000000703.Peer-Reviewed Original ResearchPulmonary artery pulsatility indexAcute decompensated heart failureAortic pulsatility indexDecompensated heart failureBaseline eGFREGFR slopePulmonary arteryPulsatility indexHeart failureLower pulmonary artery pulsatility indexKidney functionPatients admitted with acute decompensated heart failureMedian follow-up timeMultivariate Cox proportional hazards modelHemodynamic markersArtery pulsatility indexRisk of dialysisFollow-up timeLeft ventricular functionFollow-up periodCox proportional hazards modelsAssociated with higher hazardsProportional hazards modelUnique patient admissionsQuaternary medical centerBiomarker Panels for Discriminating Risk of CKD Progression in Children
Greenberg J, Abraham A, Xu Y, Schelling J, Coca S, Schrauben S, Wilson F, Waikar S, Vasan R, Gutiérrez O, Shlipak M, Ix J, Warady B, Kimmel P, Bonventre J, Parikh C, Denburg M, Furth S. Biomarker Panels for Discriminating Risk of CKD Progression in Children. Journal Of The American Society Of Nephrology 2025, 36: 1105-1115. PMID: 39820177, PMCID: PMC12147970, DOI: 10.1681/asn.0000000602.Peer-Reviewed Original ResearchPlasma KIM-1CKD progressionKIM-1Alpha 1-microglobulinUrine albumin/creatinineBaseline urine protein-to-creatinine ratiosBiomarker panelRisk factorsRisk of CKD progressionAssociated with CKD progressionUrine alpha-1-microglobulinRisk group classificationProtein-to-creatinine ratioUrine protein-to-creatinine ratioClinical risk factorsChildren 6 monthsHigh-risk groupUrine KIM-1Clinically relevant biomarkersConventional risk factorsCombination of biomarkersTubular healthBaseline eGFRMedian ageEGFR decline
2024
Peak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M. Peak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Kidney International Reports 2024, 9: 3035-3044. PMID: 39430198, PMCID: PMC11489825, DOI: 10.1016/j.ekir.2024.07.009.Peer-Reviewed Original ResearchLeft ventricular ejection fractionPulmonary artery pressureCreatinine doublingEGFR declineEjection fractionKidney outcomesHeart failurePeak tricuspid regurgitant jet velocityDoubling of serum creatinineTricuspid regurgitant jet velocityElevated pulmonary artery pressureAssociated with lower eGFRWorsening kidney functionVentricular ejection fractionRegurgitant jet velocityCox proportional hazards modelsProportional hazards modelPost Hoc AnalysisBaseline eGFRSerum creatinineLow eGFRTOPCAT trialFollow-upKidney functionArterial pressureImpact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF
Martens P, Greene S, Mentz R, Li S, Wojdyla D, Kapelios C, Mullens W, Hall M, Ketema F, Kim D, Eisenstein E, Anstrom K, Fang J, Pitt B, Velazquez E, Tang W. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1242-1250. PMID: 38558520, DOI: 10.1002/ejhf.3207.Peer-Reviewed Original ResearchEffect of torsemideBaseline renal functionRenal functionHeart failureKCCQ-CSSRandomized patientsKansas City Cardiomyopathy Questionnaire clinical summary scoreSpectrum of renal functionBaseline kidney dysfunctionCategories of estimated glomerular filtration rateTrial randomized patientsClinical summary scoreAdverse clinical outcomesGlomerular filtration rateAll-Cause MortalityTreatment effect modificationModify treatment effectsPost Hoc AnalysisPatient-reported outcomesDiuretic efficacyBaseline eGFRNo significant differenceClinical outcomesKidney dysfunctionFiltration rateDecline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsEGFR declineGlomerular filtration rateEjection fractionHeart failurePrespecified analysisFiltration rateMonths 1Estimated glomerular filtration rateDapagliflozin-treated patientsKidney composite outcomePrimary cardiovascular outcomeHeart Failure TrialChronic kidney diseaseCotransporter 2 inhibitorsInternational multicenter studyLives of patientsBaseline eGFRKidney eventsKidney outcomesCardiovascular outcomesComposite outcomePrognostic factorsFailure TrialMulticenter study
2022
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
Moura F, Wiviott S, Chertow G, Dwyer J, Gause-Nilsson I, Johansson P, Langkilde A, McMurray J, Mosenzon O, Raz I, Rossing P, Wheeler D, Sabatine M, Heerspink H. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. European Heart Journal 2022, 43: ehac544.2407. DOI: 10.1093/eurheartj/ehac544.2407.Peer-Reviewed Original ResearchUrinary albumin:creatinine ratioEffects of dapagliflozinSodium-glucose co-transporter 2Kidney eventsType 2 diabetes mellitusDAPA-CKD trialKidney endpointsBaseline eGFRAbsolute rate differenceDAPA-CKDKidney functionHigh urinary albumin:creatinine ratioPatient yearsPooled analysisPatients type 2 diabetes mellitusCardiovascular deathSubgroups of baseline eGFRPatient-level pooled analysisAlbumin:creatinine ratioLevel of kidney functionFollow-up timeCategories of eGFRBaseline kidney functionHigh cardiovascular riskAbsolute risk reduction864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED
INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.Peer-Reviewed Original ResearchGlucose-lowering medicationsPre-specified subgroupsNovartis Pharmaceuticals CorporationGlaxoSmithKline plcDaiichi SankyoDual SGLT1Baseline A1CBaseline eGFRPfizer Inc.Bristol-Myers Squibb CompanyLexicon PharmaceuticalsOutcome trialsCSL BehringNovo NordiskNovartis AGAdvanced chronic kidney diseaseType 2 diabetes patientsEli LillyAmgen Inc.Lower baseline eGFROverall trial populationCKD stage 4Primary composite outcomeSpeakers bureauCardiovascular outcome trials
2021
Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study
Hsu C, Gupta S, Tighiouart H, Goyal N, Faugno A, Tariq A, Raichoudhury R, Sharma J, Meyer L, Kshirsagar R, Jose A, Leaf D, Weiner D, Investigators S, Gupta H, Faugno G, Raichoudhury T, Meyer S, Leaf K, Walther C, Anumudu S, Arunthamakun J, Kopecky K, Milligan G, McCullough P, Nguyen T, Shaefi S, Krajewski M, Shankar S, Pannu A, Valencia J, Bauer K, Waikar S, Kibbelaar Z, Athavale A, Hart P, Upadhyay S, Vohra I, Oyintayo A, Green A, Rachoin J, Schorr C, Shea L, Edmonston D, Mosher C, Shehata A, Cohen Z, Allusson V, Bambrick-Santoyo G, Bhatti N, Mehta B, Brenner A, Walters P, Go R, Rose K, Hernán M, Zhou A, Kim E, Lisk R, Chan L, Mathews K, Coca S, Altman D, Saha A, Soh H, Wen H, Bose S, Leven E, Wang J, Mosoyan G, Pattharanitima P, Gallagher E, Friedman A, Guirguis J, Kapoor R, Meshberger C, Kelly K, Parikh C, Garibaldi B, Corona-Villalobos C, Wen Y, Menez S, Malik R, Cervantes C, Gautam S, Mallappallil M, Ouyang J, John S, Yap E, Melaku Y, Mohamed I, Bajracharya S, Puri I, Thaxton M, Bhattacharya J, Wagner J, Boudourakis L, Nguyen H, Ahoubim A, Thomas L, Sirganagari D, Guru P, Kashani K, Tehranian S, Zhou Y, Bergl P, Rodriguez J, Shah J, Gupta M, Kumar P, Lazarous D, Kassaye S, Melamed M, Mocerino T, Prudhvi K, Zhu D, Levy R, Azzi Y, Fisher M, Yunes M, Sedaliu K, Golestaneh L, Brogan M, Thakkar J, Kumar N, Ross M, Chang M, Athreya A, Farag M, Schenck E, Cho S, Plataki M, Alvarez-Mulett S, Gomez-Escobar L, Pan D, Lee S, Krishnan J, Whalen W, Charytan D, Macina A, Srivastava A, Leidner A, Martinez C, Kruser J, Wunderink R, Hodakowski A, Velez J, Price-Haywood E, Matute-Trochez L, Hasty A, Mohamed M, Avasare R, Zonies D, Al-Samkari H, Leaf R, Rosovsky R, Sise M, Newman E, Abu Omar S, Pokharel K, Sharma S, Singh H, Correa S, Shaukat T, Kamal O, Wang W, Lee M, Strohbehn I, Li J, Mueller A, Redfern R, Cairl N, Naimy G, Abu-Saif A, Hall D, Bickley L, Rowan C, Madhani-Lovely F, Peev V, Reiser J, Byun J, Vissing A, Kapania E, Post Z, Patel N, Hermes J, Sutherland A, Patrawalla A, Finkel D, Danek B, Arikapudi S, Paer J, Cangialosi P, Liotta M, Radbel J, Puri S, Sunderram J, Scharf M, Ahmed A, Berim I, Vatson J, Karp G, Anand S, Levitt J, Garcia P, Boyle S, Song R, Zhang J, Woo S, Deng X, Katz-Greenberg G, Sharshir M, Rusnak V, Bansal A, Podoll A, Chonchol M, Sharma S, Burnham E, Rashidi A, Hejal R, Judd E, Latta L, Tolwani A, Albertson T, Adams J, Chang S, Beutler R, Schulze C, Macedo E, RheeKa H, Liu T, Jotwani V, Koyner J, Shah C, Jaikaransingh V, Toth-Manikowski S, Joo M, Lash J, Neyra J, Chaaban N, Elias M, Ahmad Y, Dy R, Iardino A, Au E, Sosa M, Taldone S, Contreras G, De La Zerda D, Gershengorn H, Fornoni A, Hayek S, Blakely P, Berlin H, Azam T, Shadid H, Pan M, O’Hayer P, Meloche C, Feroze R, Padalia K, Leya J, Donnelly J, Admon A, Flythe J, Tugman M, Chang E, Brown B, Leonberg-Yoo A, Spiardi R, Miano T, Roche M, Vasquez C, Bansal A, Ernecoff N, Kapoor S, Verma S, Chen H, Kovesdy C, Molnar M, Azhar A, Hedayati S, Nadamuni M, Shastri S, Willett D, Short S, Renaghan A, Enfield K, Bhatraju P, Malik A, Semler M, Vijayan A, Joy C, Li T, Goldberg S, Kao P, Schumaker G, Christov M, Griffiths J, Gupta S, Kapoor A, Chugh S, Wilson P, Arora T, Ugwuowo U. Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. American Journal Of Kidney Diseases 2021, 79: 404-416.e1. PMID: 34871701, PMCID: PMC8641974, DOI: 10.1053/j.ajkd.2021.11.004.Peer-Reviewed Original ResearchConceptsICU cohortKRT initiationKidney recoveryIll patientsSevere AKIBaseline eGFRKidney injuryCohort studyCOVID-19-associated acute kidney injuryLower baseline eGFRLower kidney functionAcute kidney injuryGlomerular filtration rateKidney replacement therapyIntensive care unitTime of dischargeCoronavirus disease 2019COVID-19AKI severityHospital dischargeClinical factorsUrine outputCare unitIllness severityKidney functionASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialKidney eventsOutcome trialsPlacebo armMyocardial infarctionType 2 diabetes mellitusLower baseline eGFRMI/strokeSubsequent CV eventsRisk of hospitalizationCoronary artery diseaseType 2 diabetesHigh uric acidUse of therapiesAssociation of kidneyBaseline eGFRCV eventsCV outcomesSubsequent HHFCardiovascular outcomesHF outcomesArtery diseaseBaseline factorsDiabetes mellitusHeart failureAssociation of AKI-D with Urinary Findings and Baseline eGFR in Hospitalized COVID-19 Patients
Patel DM, Phadke M, Dai F, Simonov M, Dahl NK, Kodali R. Association of AKI-D with Urinary Findings and Baseline eGFR in Hospitalized COVID-19 Patients. Kidney360 2021, 2: 1215-1224. PMID: 35369662, PMCID: PMC8676386, DOI: 10.34067/kid.0001612021.Peer-Reviewed Original ResearchConceptsOdds of AKIBaseline eGFRLower oddsHospital AKIInitial urinalysisHospital deathRisk factorsHospitalized COVID-19 patientsActive urine sedimentAssociation of AKIBaseline kidney functionHigher baseline eGFRCongestive heart failureCOVID-19 patientsCoronavirus disease 2019COVID-19Electronic health recordsAKI statusUrinary findingsInflammatory markersUrinalysis findingsHeart failurePatient characteristicsKidney functionDisease 2019Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease
Liu J, Tio M, Verma A, Schmidt I, Ilori T, Knauf F, Mc Causland F, Waikar S. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e281-e292. PMID: 34390334, PMCID: PMC8684460, DOI: 10.1210/clinem/dgab574.Peer-Reviewed Original ResearchConceptsUrinary calcium excretionChronic kidney diseaseEnd-stage kidney diseaseCalcium excretionKidney diseaseChronic Renal Insufficiency Cohort (CRIC) StudyIncident end-stage kidney diseaseLevel of CKDSelf-identified black raceAtherosclerotic cardiovascular disease eventsSerum parathyroid hormoneCardiovascular disease eventsAdverse clinical eventsAdverse clinical outcomesStage kidney diseaseBaseline eGFRCKD progressionUrinary sodiumCause mortalityCohort studyLoop diureticsThiazide diureticsClinical outcomesParathyroid hormoneVascular calcificationA Comparison Study of Coronavirus Disease 2019 Outcomes in Hospitalized Kidney Transplant Recipients.
Mansour SG, Malhotra D, Simonov M, Yamamoto Y, Arora T, Subair L, Alausa J, Moledina DG, Greenberg JH, Wilson FP, Marin EP. A Comparison Study of Coronavirus Disease 2019 Outcomes in Hospitalized Kidney Transplant Recipients. Kidney360 2021, 2: 494-506. PMID: 35369023, PMCID: PMC8786009, DOI: 10.34067/kid.0005652020.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsHospital complicationsVasopressor useSARS-CoV-2Baseline eGFRTransplant recipientsElixhauser scoreBlack raceSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Coronavirus disease 2019 (COVID-19) outcomesRespiratory syndrome coronavirus 2High ferritin levelsSyndrome coronavirus 2High rateElectronic health recordsFerritin levelsComparator groupCoronavirus 2Higher oddsViral infectionLarger sample sizeHigh mortalityComplicationsAKIRace Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis
Mahmud N, Asrani SK, Reese PP, Kaplan DE, Taddei TH, Nadim MK, Serper M. Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis. Digestive Diseases And Sciences 2021, 67: 1399-1408. PMID: 33761091, PMCID: PMC8460692, DOI: 10.1007/s10620-021-06943-1.Peer-Reviewed Original ResearchConceptsAcute kidney injuryBaseline eGFREGFR equationsRace adjustmentAKI eventsCKD-EPIGlomerular filtration rate estimating equationsChronic Kidney Disease Epidemiology CollaborationAcute kidney injury eventsIncident acute kidney injuryRetrospective national cohort studyLower baseline eGFRNational cohort studyHigh rateAscites criteriaKidney injuryLower eGFRCohort studyClinical outcomesBlack raceCirrhosisDrug dosingInjury eventsMuscle massPatients
2020
Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma
Meagher M, Lane B, Capitanio U, Mehrazin R, Bradshaw A, Noyes S, Larcher A, Eldefrawy A, Ghali F, Patel D, Bruinius J, Dutt R, Keiner C, Miller N, Wan F, Montorsi F, Derweesh I. Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World Journal Of Urology 2020, 39: 1195-1201. PMID: 32556559, DOI: 10.1007/s00345-020-03299-5.Peer-Reviewed Original ResearchConceptsDe novo chronic kidney diseaseChronic kidney diseaseKaplan-Meier analysisPartial nephrectomyActive surveillanceMultivariable analysisBaseline eGFRTumor sizeFunctional outcomeFunctional declineCKD-free survivalGreater functional declineHigher RENAL scoreLower baseline eGFRRenal functional preservationRegression multivariable analysisClinical tumor sizeRenal functional outcomesTumor diameterKidney diseaseRENAL scoreFunctional preservationMedian changeRetrospective analysisSelect circumstancesClinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study
Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study. Journal Of The American Society Of Nephrology 2020, 31: 435-446. PMID: 31896554, PMCID: PMC7003302, DOI: 10.1681/asn.2019070676.Peer-Reviewed Original ResearchConceptsExtrarenal immune-related adverse eventsImmune-related adverse eventsMulticenter studyRenal prognosisKidney recoveryAdverse eventsMost patientsClinical featuresCombination immune checkpoint inhibitor therapyImmune checkpoint inhibitor initiationImmune checkpoint inhibitor rechallengeImmune checkpoint inhibitor therapyProton pump inhibitor useComplication of immunotherapyLower baseline eGFRNew dialysis requirementWorse renal prognosisCheckpoint inhibitor therapyImmune checkpoint inhibitorsCheckpoint inhibitor initiationBaseline eGFRSubnephrotic proteinuriaCheckpoint inhibitorsDialysis requirementControl patients
2017
Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, Alpern R. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD. Clinical Journal Of The American Society Of Nephrology 2017, 13: 26-35. PMID: 29102959, PMCID: PMC5753317, DOI: 10.2215/cjn.07300717.Peer-Reviewed Original ResearchConceptsSerum bicarbonateEnd of treatmentMetabolic acidosisTreatment groupsBaseline serum bicarbonateMean baseline eGFRMEq/LSignificant adverse effectsBaseline eGFRGastrointestinal eventsAdverse eventsFirst doseControlled TrialsHeart failurePatientsCKDBaseline levelsMean increaseAbstractTextUnit studiesAcidosisAdverse effectsPlaceboTreatmentDaysEffect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD
Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, Brancale J, Xu D, Wisocky J, Lin MV, Kim AY, Thadhani R, Chung RT. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Clinical Journal Of The American Society Of Nephrology 2017, 12: 1615-1623. PMID: 28882857, PMCID: PMC5628711, DOI: 10.2215/cjn.02510317.Peer-Reviewed Original ResearchConceptsSustained virologic responseAdverse eventsVirologic responseAntiviral therapyOverall sustained virologic responsePrior solid organ transplantHepatitis C virus (HCV) therapyEffect of sofosbuvirEfficacy of sofosbuvirHepatitis C cureRetrospective observational cohortC virus infectionSerious adverse eventsSolid organ transplantsC virus therapyCohort of patientsLarge health care systemPost-treatment followHepatitis C virusHealth care systemBaseline eGFRTreatment discontinuationObservational cohortKidney functionRegression models
2016
The Effect of Chronic Kidney Disease on a Physical Activity Intervention: Impact on Physical Function, Adherence, and Safety
Liu C, Milton J, Hsu F, Beavers K, Yank V, Church T, Shegog J, Kashaf S, Nayfield S, Newman A, Stafford R, Nicklas B, Weiner D, Fielding R, Group L. The Effect of Chronic Kidney Disease on a Physical Activity Intervention: Impact on Physical Function, Adherence, and Safety. Journal Of Clinical Nephrology And Renal Care 2016, 3: 21. PMID: 29745380, PMCID: PMC5937279, DOI: 10.23937/2572-3286.1510021.Peer-Reviewed Original ResearchShort Physical Performance BatteryChronic kidney diseaseSerious adverse eventsPhysical activity programPhysical activity interventionsCKD participantsOlder adultsKidney diseaseActivity interventionsPhysical activityBaseline short physical performance batteryMean SPPBTypes of SAEsBaseline chronic kidney diseaseLIFE-P studyNon-CKD participantsPhysical Performance BatteryPhysical function deficitsInteraction of interventionBaseline eGFRMean eGFRAdverse eventsSecondary outcomesPhysical functionLow adherence
2015
Urine Biomarkers and Perioperative Acute Kidney Injury: The Impact of Preoperative Estimated GFR
Koyner JL, Coca SG, Thiessen-Philbrook H, Patel UD, Shlipak MG, Garg AX, Parikh CR, Consortium T, Raman J, Jeevanandam V, Akhter S, Devarajan P, Bennett M, Ma Q, Griffiths R, Edelstein C, Passik C, Nagy J, Swaminathan M, Chu M, Goldbach M, Guo L, McKenzie N, Myers M, Novick R, Quantz M, Schumann V, Webster L, Zappitelli M, Palijan A, Dewar M, Darr U, Hashim S, Elefteriades J, Geirsson A, Garwood S, Kemp R, Butrymowicz I. Urine Biomarkers and Perioperative Acute Kidney Injury: The Impact of Preoperative Estimated GFR. American Journal Of Kidney Diseases 2015, 66: 1006-1014. PMID: 26386737, PMCID: PMC4658239, DOI: 10.1053/j.ajkd.2015.07.027.Peer-Reviewed Original ResearchConceptsAcute kidney injurySevere acute kidney injuryPost-operative dialysisBaseline eGFRKidney injuryInterleukin-18Urinary biomarkersDevelopment of AKIAKI Network stage 1Clinical acute kidney injuryPerioperative acute kidney injuryKidney injury molecule-1Liver-type fatty acid binding proteinBaseline kidney functionImpact of PreoperativeSerum creatinine levelsHours of surgeryInjury molecule-1Prospective cohort studyGlomerular filtration rateNumber of patientsPerformance of biomarkersFatty acid binding proteinAdjusted RRsPreoperative eGFR
2013
Influence of Age-Related Versus Non–Age-Related Renal Dysfunction on Survival in Patients With Left Ventricular Dysfunction
Testani JM, Brisco MA, Han G, Laur O, Kula AJ, Cheng SJ, Tang WH, Parikh CR. Influence of Age-Related Versus Non–Age-Related Renal Dysfunction on Survival in Patients With Left Ventricular Dysfunction. The American Journal Of Cardiology 2013, 113: 127-131. PMID: 24216124, PMCID: PMC3915785, DOI: 10.1016/j.amjcard.2013.09.029.Peer-Reviewed Original ResearchConceptsLow glomerular filtration rateGlomerular filtration rateVentricular dysfunctionRenal dysfunctionNormal agingLeft ventricular dysfunctionRisk of deathNormal aging resultsAge-related decreaseInfluence of ageBaseline eGFRMean eGFRLower eGFRWorsened survivalPrognostic importanceFiltration rateSurvival disadvantagePrimary analysisDysfunctionEGFRSignificant riskPatientsUnderlying mechanismRiskMortality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply